Importance: Some studies have reported negative effects of prior-season influenza vaccination. Prior-season influenza vaccination effects on vaccine effectiveness (VE) in children are not well understood. Objective: To assess the association of prior-season influenza vaccination with subsequent VE in children aged 2 to 17 years. Design, Setting, and Participants: This multiseason, test-negative case-control study was conducted in outpatient clinics at 4 US sites among children aged 2 to 17 years with a medically attended febrile acute respiratory illness. Participants were recruited during the 2013-2014, 2014-2015, and 2015-2016 seasons when influenza circulated locally. Cases were children with influenza confirmed by reverse-transcription polymerase chain reaction. Test-negative control individuals were children with negative test results for influenza. Exposures: Vaccination history, including influenza vaccine type received in the enrollment season (live attenuated influenza vaccine [LAIV], inactivated influenza vaccine [IIV], or no vaccine) and season before enrollment (LAIV, IIV, or no vaccine), determined from medical records and immunization registries. Main Outcomes and Measures: LAIV and IIV effectiveness by influenza type and subtype (influenza A[H1N1]pdm09, influenza A[H3N2], or influenza B), estimated as 100 × (1 - odds ratio) in a logistic regression model with adjustment for potential confounders. Prior season vaccination associations were assessed with an interaction term. Results: Of 3369 children (1749 [52%] male; median age, 6.6 years [range, 2-17 years]) included in the analysis, 772 (23%) had a positive test result for influenza and 1674 (50%) were vaccinated in the enrollment season. Among LAIV recipients, VE against influenza A(H3N2) was higher among children vaccinated in both the enrollment and 1 prior season (50.3% [95% CI, 17.0% to 70.2%]) than among those without 1 prior season vaccination (-82.4% [95% CI, -267.5% to 9.5%], interaction P < .001). The effectiveness of LAIV against influenza A(H1N1)pdm09 was not associated with prior season vaccination among those with prior season vaccination (47.5% [95% CI, 11.4% to 68.9%]) and among those without prior season vaccination (7.8% [95% CI, -101.9% to 57.9%]) (interaction P = .37). Prior season vaccination was not associated with effectiveness of IIV against influenza A(H3N2) (38.7% [95% CI, 6.8% to 59.6%] among those with prior-season vaccination and 23.2% [95% CI, -38.3% to 57.4%] among those without prior-season vaccination, interaction P = .16) or with effectiveness of IIV against influenza A[H1N1]pdm09 (72.4% [95% CI, 56.0% to 82.7%] among those with prior season vaccination and 67.5% [95% CI, 32.1% to 84.4%] among those without prior season vaccination, interaction P = .93). Residual protection from prior season vaccination only (no vaccination in the enrollment season) was observed for influenza B (LAIV: 60.0% [95% CI, 36.8% to 74.7%]; IIV: 60.0% [36.9% to 74.6%]). Similar results were observed in analyses that included repeated vaccination in 2 and 3 prior seasons. Conclusions and Relevance: Influenza VE varied by influenza type and subtype and vaccine type, but prior-season vaccination was not associated with reduced VE. These findings support current recommendations for annual influenza vaccination of children.
Importance: Some studies have reported negative effects of prior-season influenza vaccination. Prior-season influenza vaccination effects on vaccine effectiveness (VE) in children are not well understood. Objective: To assess the association of prior-season influenza vaccination with subsequent VE in children aged 2 to 17 years. Design, Setting, and Participants: This multiseason, test-negative case-control study was conducted in outpatient clinics at 4 US sites among children aged 2 to 17 years with a medically attended febrile acute respiratory illness. Participants were recruited during the 2013-2014, 2014-2015, and 2015-2016 seasons when influenza circulated locally. Cases were children with influenza confirmed by reverse-transcription polymerase chain reaction. Test-negative control individuals were children with negative test results for influenza. Exposures: Vaccination history, including influenza vaccine type received in the enrollment season (live attenuated influenza vaccine [LAIV], inactivated influenza vaccine [IIV], or no vaccine) and season before enrollment (LAIV, IIV, or no vaccine), determined from medical records and immunization registries. Main Outcomes and Measures: LAIV and IIV effectiveness by influenza type and subtype (influenza A[H1N1]pdm09, influenza A[H3N2], or influenza B), estimated as 100 × (1 - odds ratio) in a logistic regression model with adjustment for potential confounders. Prior season vaccination associations were assessed with an interaction term. Results: Of 3369 children (1749 [52%] male; median age, 6.6 years [range, 2-17 years]) included in the analysis, 772 (23%) had a positive test result for influenza and 1674 (50%) were vaccinated in the enrollment season. Among LAIV recipients, VE against influenza A(H3N2) was higher among children vaccinated in both the enrollment and 1 prior season (50.3% [95% CI, 17.0% to 70.2%]) than among those without 1 prior season vaccination (-82.4% [95% CI, -267.5% to 9.5%], interaction P < .001). The effectiveness of LAIV against influenza A(H1N1)pdm09 was not associated with prior season vaccination among those with prior season vaccination (47.5% [95% CI, 11.4% to 68.9%]) and among those without prior season vaccination (7.8% [95% CI, -101.9% to 57.9%]) (interaction P = .37). Prior season vaccination was not associated with effectiveness of IIV against influenza A(H3N2) (38.7% [95% CI, 6.8% to 59.6%] among those with prior-season vaccination and 23.2% [95% CI, -38.3% to 57.4%] among those without prior-season vaccination, interaction P = .16) or with effectiveness of IIV against influenza A[H1N1]pdm09 (72.4% [95% CI, 56.0% to 82.7%] among those with prior season vaccination and 67.5% [95% CI, 32.1% to 84.4%] among those without prior season vaccination, interaction P = .93). Residual protection from prior season vaccination only (no vaccination in the enrollment season) was observed for influenza B (LAIV: 60.0% [95% CI, 36.8% to 74.7%]; IIV: 60.0% [36.9% to 74.6%]). Similar results were observed in analyses that included repeated vaccination in 2 and 3 prior seasons. Conclusions and Relevance: Influenza VE varied by influenza type and subtype and vaccine type, but prior-season vaccination was not associated with reduced VE. These findings support current recommendations for annual influenza vaccination of children.
Authors: Xiao-Song He; Tyson H Holmes; Caiqiu Zhang; Kutubuddin Mahmood; George W Kemble; David B Lewis; Cornelia L Dekker; Harry B Greenberg; Ann M Arvin Journal: J Virol Date: 2006-09-13 Impact factor: 5.103
Authors: Paula A Lanthier; Gail E Huston; Amy Moquin; Sheri M Eaton; Frank M Szaba; Lawrence W Kummer; Micheal P Tighe; Jacob E Kohlmeier; Patrick J Blair; Michael Broderick; Stephen T Smiley; Laura Haynes Journal: Vaccine Date: 2011-08-02 Impact factor: 3.641
Authors: Edward A Belongia; Danuta M Skowronski; Huong Q McLean; Catharine Chambers; Maria E Sundaram; Gaston De Serres Journal: Expert Rev Vaccines Date: 2017-06-09 Impact factor: 5.217
Authors: Edward A Belongia; Maria E Sundaram; David L McClure; Jennifer K Meece; Jill Ferdinands; Jeffrey J VanWormer Journal: Vaccine Date: 2014-06-21 Impact factor: 3.641
Authors: J Castilla; I Martínez-Baz; V Martínez-Artola; G Reina; F Pozo; M García Cenoz; M Guevara; J Morán; F Irisarri; M Arriazu; E Albéniz; C Ezpeleta; A Barricarte Journal: Euro Surveill Date: 2013-01-31
Authors: Ritva K Syrjänen; Jukka Jokinen; Thedi Ziegler; Jonas Sundman; Mika Lahdenkari; Ilkka Julkunen; Terhi M Kilpi Journal: PLoS One Date: 2014-09-29 Impact factor: 3.240
Authors: Krissy K Moehling; Richard K Zimmerman; Mary Patricia Nowalk; Chyongchiou Jeng Lin; Judith M Martin; John F Alcorn; Michael Susick; Ashley Burroughs; Crystal Holiday; Brendan Flannery; Min Z Levine Journal: Vaccine Date: 2020-06-21 Impact factor: 3.641
Authors: Inci Yildirim; Carol M Kao; Ashley Tippett; Piyarat Suntarattiwong; Mohamed Munye; Jumi Yi; Mohnd Elmontser; Elizabeth Quincer; Chris Focht; Nora Watson; Hande Bilen; Julia M Baker; Ben Lopman; Elena Hogenesch; Christina A Rostad; Evan J Anderson Journal: Clin Infect Dis Date: 2021-11-16 Impact factor: 20.999
Authors: Kelsey Florek; James Mutschler; Huong Q McLean; Jennifer P King; Brendan Flannery; Edward A Belongia; Thomas C Friedrich Journal: Vaccine Date: 2019-11-18 Impact factor: 3.641
Authors: Huong Q McLean; Jennifer P King; Pamela Talley; Brendan Flannery; Sarah Spencer; Min Z Levine; Thomas C Friedrich; Edward A Belongia Journal: J Pediatric Infect Dis Soc Date: 2020-04-30 Impact factor: 3.164
Authors: Michael Hinojosa; Samuel S Shepard; Jessie R Chung; Jennifer P King; Huong Q McLean; Brendan Flannery; Edward A Belongia; Min Z Levine Journal: J Infect Dis Date: 2021-08-02 Impact factor: 5.226